Successful combination therapy of mepolizumab and dupilumab in a patient with EGPA: a future therapeutic option?
作者信息
Martins-Martinho Joana, Pereira da Costa Roberto, Abreu Tiago, Ponte Cristina
机构信息
Rheumatology Department, Unidade Local de Saúde Santa Maria, Lisbon, Portugal.
Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
出版信息
Rheumatol Adv Pract. 2024 Aug 6;8(3):rkae093. doi: 10.1093/rap/rkae093. eCollection 2024.
Abstract
摘要
相似文献
1
Successful combination therapy of mepolizumab and dupilumab in a patient with EGPA: a future therapeutic option?美泊利单抗和度普利尤单抗联合治疗嗜酸性肉芽肿性多血管炎患者成功：一种未来的治疗选择？
Rheumatol Adv Pract. 2024 Aug 6;8(3):rkae093. doi: 10.1093/rap/rkae093. eCollection 2024.
2
A case of dupilumab combination therapy for exacerbation of atopic dermatitis in a patient with eosinophilic granulomatosis with polyangiitis treated with mepolizumab.一例美泊利珠单抗治疗嗜酸性肉芽肿性多血管炎患者中重度特应性皮炎恶化后接受度普利尤单抗联合治疗的病例。
Mod Rheumatol Case Rep. 2023 Dec 29;8(1):159-162. doi: 10.1093/mrcr/rxad059.
3
Eosinophilic granulomatosis polyangiitis (EGPA) complicated with periaortitis, precipitating role of dupilumab? A case report a review of the literature.嗜酸性肉芽肿性多血管炎（EGPA）并发大动脉炎，度普利尤单抗的诱发作用？病例报告及文献复习。
RMD Open. 2023 Sep;9(3). doi: 10.1136/rmdopen-2023-003300.
4
Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study.度普利尤单抗用于治疗嗜酸性肉芽肿性多血管炎的复发性或难治性鼻窦和/或哮喘表现：一项欧洲回顾性研究。
Ann Rheum Dis. 2023 Dec;82(12):1587-1593. doi: 10.1136/ard-2023-224756. Epub 2023 Sep 21.
5
Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?美泊利珠单抗作为嗜酸性肉芽肿性多血管炎（EGPA）的糖皮质激素节约剂：较低剂量是否足够？
J Asthma. 2021 Dec;58(12):1675-1679. doi: 10.1080/02770903.2020.1827417. Epub 2020 Oct 1.
6
Mepolizumab as an effective treatment in a case of hypophysitis in eosinophilic granulomatosis with polyangiitis.美泊利单抗治疗嗜酸性肉芽肿性多血管炎合并垂体炎1例疗效观察
Ther Adv Neurol Disord. 2023 Jun 22;16:17562864231182519. doi: 10.1177/17562864231182519. eCollection 2023.
7
Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis.一名处于缓解期且患有持续性鼻息肉的嗜酸性肉芽肿性多血管炎（EGPA）患者成功从美泊利单抗转换为度普利尤单抗治疗。
Rheumatology (Oxford). 2024 Mar 1;63(3):e96-e98. doi: 10.1093/rheumatology/kead479.
8
Rituximab and dupilumab improve eosinophilic granulomatosis with polyangiitis with multiple pulmonary thrombi.利妥昔单抗和度普利尤单抗可改善伴有多发性肺血栓的嗜酸性肉芽肿性多血管炎。
Allergy Asthma Clin Immunol. 2022 Feb 26;18(1):18. doi: 10.1186/s13223-021-00639-x.
9
Coexistence of Eosinophilic Granulomatosis With Polyangiitis and Allergic Bronchopulmonary Aspergillosis: A Fascinating Relationship.嗜酸性肉芽肿性多血管炎与变应性支气管肺曲霉病并存：一种引人入胜的关系。
Cureus. 2024 Apr 9;16(4):e57917. doi: 10.7759/cureus.57917. eCollection 2024 Apr.
10
Characteristics and Disease Burden of Patients With Eosinophilic Granulomatosis With Polyangiitis Initiating Mepolizumab in the United States.在美国，接受美泊利珠单抗治疗的嗜酸性肉芽肿伴多血管炎患者的特征和疾病负担。
J Clin Rheumatol. 2023 Dec 1;29(8):381-387. doi: 10.1097/RHU.0000000000002033. Epub 2023 Oct 2.
本文引用的文献
1
Dual biologics for severe asthma and atopic dermatitis: Synopsis of two cases and literature review.用于重度哮喘和特应性皮炎的双特异性生物制剂：两例病例概述及文献综述
Respirol Case Rep. 2023 Dec 6;12(1):e01266. doi: 10.1002/rcr2.1266. eCollection 2024 Jan.
2
A case of dupilumab combination therapy for exacerbation of atopic dermatitis in a patient with eosinophilic granulomatosis with polyangiitis treated with mepolizumab.一例美泊利珠单抗治疗嗜酸性肉芽肿性多血管炎患者中重度特应性皮炎恶化后接受度普利尤单抗联合治疗的病例。
Mod Rheumatol Case Rep. 2023 Dec 29;8(1):159-162. doi: 10.1093/mrcr/rxad059.
3
Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study.度普利尤单抗用于治疗嗜酸性肉芽肿性多血管炎的复发性或难治性鼻窦和/或哮喘表现：一项欧洲回顾性研究。
Ann Rheum Dis. 2023 Dec;82(12):1587-1593. doi: 10.1136/ard-2023-224756. Epub 2023 Sep 21.
4
Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making.重度慢性鼻-鼻窦炎伴鼻息肉和重度哮喘患者生物治疗转换或联合使用的评估。临床决策考量
Expert Rev Clin Immunol. 2023 Jul-Dec;19(8):1041-1049. doi: 10.1080/1744666X.2023.2218617. Epub 2023 May 29.
5
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.EULAR 推荐的抗中性粒细胞胞浆抗体相关性血管炎治疗：2022 年更新。
Ann Rheum Dis. 2024 Jan 2;83(1):30-47. doi: 10.1136/ard-2022-223764.
6
A case series of dual biologics therapy for severe asthma.
J Allergy Clin Immunol Pract. 2023 Jan;11(1):335-340.e2. doi: 10.1016/j.jaip.2022.09.036. Epub 2022 Oct 7.
7
Dupilumab-Associated Eosinophilic Granulomatosis With Polyangiitis.度普利尤单抗相关的嗜酸性肉芽肿性多血管炎
Cureus. 2022 Aug 4;14(8):e27670. doi: 10.7759/cureus.27670. eCollection 2022 Aug.
8
Safety of combining biologics in severe asthma: Asthma-related and unrelated combinations.重度哮喘中生物制剂联合使用的安全性：与哮喘相关及不相关的联合用药
Allergy. 2022 Sep;77(9):2839-2843. doi: 10.1111/all.15379. Epub 2022 Jun 4.
9
Successful concomitant therapy with mepolizumab and dupilumab for atypical eosinophilic granulomatosis with polyangiitis.美泊利单抗和度普利尤单抗联合治疗非典型嗜酸性肉芽肿性多血管炎取得成功。
Allergol Int. 2022 Apr;71(2):259-261. doi: 10.1016/j.alit.2021.11.003. Epub 2022 Jan 21.
10
Cycling biologic therapy for severe asthma.重度哮喘的循环生物疗法。
Pulmonology. 2022 Jan-Feb;28(1):65-67. doi: 10.1016/j.pulmoe.2021.07.009. Epub 2021 Oct 6.
Zotero 插件